A phase II trial of Octreotate-Lu-177-DOTA-Tyr-3 in patients with various inoperable, somatostatin receptor positive NETs including bronchial carcinoid tumors

Trial Profile

A phase II trial of Octreotate-Lu-177-DOTA-Tyr-3 in patients with various inoperable, somatostatin receptor positive NETs including bronchial carcinoid tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
  • Indications Carcinoid tumour; Neuroendocrine tumours; Paraganglioma; Pheochromocytoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Sep 2017 According to an Advanced Accelerator Applications media release, the European Commission (EC) has approved the marketing authorization of lutetium (177Lu) oxodotreotide (Lutathera) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. The approval is based on results from this and NETTER-1 trials.
    • 27 Jul 2017 According to an Advanced Accelerator Applications media release, the company has resubmitted the New Drug Application for Lutathera to the US Food and Drug Administration. The company has resubmitted the NDA following receipt of a complete response letter from the FDA in December 2016, in which the Agency cited issues with the format, traceability, uniformity, and completeness relating to the NETTER-1 and Erasmus clinical datasets.
    • 21 Jul 2017 According to an Advanced Accelerator Applications media release, the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the marketing authorization of lutetium (177Lu) oxodotreotide (Lutathera) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top